Stocks › Biotechnology › WVE

Wave Life Sciences WVE

US equityMarket cap rank #3510Biotechnology

$3.54 +$0.02 (+0.57%)

Pre-market · Oct 8, 6:20 am ET · After hours $3.54 -0.06%

Open$3.48

Prev close$3.52

Day range$3.43 – $3.60

Volume3.05M

Market cap$697.55M

P/E (TTM)–

Dividend yield–

Ownership & positioning

Who holds it, who is betting against it, and where the big money is moving

Institutional ownership99.9%-3.13 pts vs. prior quarter

Institutions holding287-2 vs. prior quarter

Insider trades (recent)18 buys / 27 sellsNet selling

Short interest8.95% of floatDays to cover 5.2 · as of 15 Sep 2026

Short-sale volume share17.3%5-day average of daily volume

Short-sale volume as % of daily volume

Large-order net flow, last 20 sessions

Net of large-order buying minus selling, in USD. Over this window: +$3.60M (14 inflow days, 6 outflow days).

Net flow by order size, last 20 sessions

Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.

The five largest holders on file together own 42.8% of shares outstanding.

Largest holders

RA Capital Management, L.P.13.69%
BlackRock9.75%
GSK Equity Investments, Limited9.26%
Maverick Capital, Ltd.5.22%
Shin Nippon Biomedical Laboratories, Ltd.4.88%
Driehaus Capital Management LLC2.76%
PRIMECAP Management Company2.72%
683 Capital Management, LLC2.51%

By investor type

Mutual Fund40.04%
Hedge Fund25.90%
VC/PE Fund24.38%
Public Company7.60%
Private Company1.32%
Individual/Insider0.41%
Government Pension Fund0.25%
Insurance Company0.23%

Reported short interest has fallen from 10.86% to 8.95% of float over the last 6 biweekly reports (30 Jun 2026 to 15 Sep 2026).

Recent institutional activity

Holder	Type	Period	Share change	New stake
BlackRock	Mutual Fund	2026/Q3	+5,085,049	9.7%
Readystate Asset Management LP	Hedge Fund	2026/Q3	+4,727,139	2.4%
Qube Research & Technologies Ltd	Mutual Fund	2026/Q3	+2,620,076	1.4%
Two Sigma Investments, LP	Hedge Fund	2026/Q3	+1,829,571	1.9%
Dimensional Fund Advisors	Mutual Fund	2026/Q3	+1,707,809	0.9%
D. E. Shaw & Co., L.P.	Hedge Fund	2026/Q3	+1,699,923	0.9%
Algert Global LLC	Hedge Fund	2026/Q3	+1,502,026	1.4%
Point72 Asset Management, L.P.	Hedge Fund	2026/Q3	+1,484,989	0.8%
AQR Capital Management	Hedge Fund	2026/Q3	+1,196,078	0.8%
State Street Global Advisors	Mutual Fund	2026/Q3	+1,165,284	2.5%
Renaissance Technologies Corp.	Hedge Fund	2026/Q3	+1,107,300	0.9%
Squarepoint OPS LLC	Hedge Fund	2026/Q3	+1,079,052	1.3%
Morgan Stanley	Public Company	2026/Q3	+1,059,023	1.2%
Vanguard Portfolio Management, LLC	Mutual Fund	2026/Q3	+934,544	1.1%
Millennium Management LLC	Hedge Fund	2026/Q3	+839,041	0.9%

Institutional buy/sell activity by reporting period, largest moves first.

Insider transactions

Date	Insider	Title	Transaction	Shares	Price	Held after
11 Aug 2026	Adrian George Rawcliffe	Independent Director	Automatic Disposition	-12,700	$5.29	–
10 Aug 2026	Ken Takanashi	Independent Director	Automatic Disposition	-3,864	$6.01	20,079
10 Aug 2026	Heidi L. Wagner	Independent Director	Derivative Exercise and Sale	-7,000	$6.01	44,930
10 Aug 2026	Aik Na Tan	Independent Director	Automatic Disposition	-432	$6.01	24,968
8 Apr 2026	Christopher I. Wright	Chief Medical Officer	Initial Statement of Beneficial	+0	–	45,625
8 Apr 2026	Erik Ingelsson	Chief Scientific Officer	Initial Statement of Beneficial	+0	–	70,375
29 Mar 2026	RA Capital Management, L.P.		Open Market Acquisition	+8,772,496	$6.50	26,975,505
22 Mar 2026	Shin Nippon Biomedical Laboratories, Ltd.		Derivative Exercise and Retained	+3,901,348	–	9,606,408
25 Feb 2026	Christopher Francis	Senior VP of Corporate Development & Head of Emerging Areas	Derivative Exercise and Sale	-33,194	$15.09	4,367
8 Feb 2026	Chandra Vargeese	CTO & Head of Platform Discovery Sciences	Open Market Disposition	-3,228	$13.45	334,871
8 Feb 2026	Kyle B. Moran	Chief Financial Officer	Open Market Disposition	-3,588	$13.45	57,260
8 Feb 2026	Paul B. Bolno	Chief Executive Officer	Open Market Disposition	-10,480	$13.45	19,770
8 Feb 2026	Christopher Francis	Senior VP of Corporate Development & Head of Emerging Areas	Open Market Disposition	-1,883	$13.45	4,367
4 Feb 2026	Chandra Vargeese	CTO & Head of Platform Discovery Sciences	Other Acquisition	+45,625	–	73,375
4 Feb 2026	Chandra Vargeese	CTO & Head of Platform Discovery Sciences	Other Derivative Acquisition	+273,750	$12.75	273,750
4 Feb 2026	Kyle B. Moran	Chief Financial Officer	Other Acquisition	+45,625	–	77,125
4 Feb 2026	Kyle B. Moran	Chief Financial Officer	Other Derivative Acquisition	+273,750	$12.75	273,750
4 Feb 2026	Paul B. Bolno	Chief Executive Officer	Other Acquisition	+165,000	–	255,750
4 Feb 2026	Paul B. Bolno	Chief Executive Officer	Other Derivative Acquisition	+1,000,000	$12.75	1,000,000
4 Feb 2026	Christopher Francis	Senior VP of Corporate Development & Head of Emerging Areas	Other Acquisition	+38,750	–	57,500

From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.

Short interest, by report

Report date	Shares short	% of float	Days to cover
15 Sep 2026	17,637,783	9.0%	5.2
31 Aug 2026	16,281,873	8.3%	5.5
14 Aug 2026	16,200,874	8.2%	4.4
31 Jul 2026	16,401,737	8.3%	7.5
15 Jul 2026	16,848,760	8.8%	6.3
30 Jun 2026	20,901,285	10.9%	5.7

Discussion

No comments yet — be the first to weigh in on WVE.